Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Flavin mononucleotide (FMN) riboswitch, also known as the RFN element, is a highly conserved regulatory RNA element found in the 5' untranslated regions of bacterial messenger RNAs (Winkler et al., 2002). It functions as a metabolite-sensing genetic switch that binds FMN with high affinity and specificity to regulate the expression of genes involved in the biosynthesis and transport of riboflavin (Serganov et al., 2009). Upon binding FMN, the riboswitch undergoes a conformational change that typically leads to the formation of a rho-independent transcription terminator or the sequestration of the ribosome-binding site, effectively shutting down gene expression (Howe et al., 2015). Because riboswitches are prevalent in bacteria but absent in humans, they represent promising targets for the development of novel classes of antibiotics (Blount & Breaker, 2006). Small molecules like the natural antibiotic Roseoflavin and the synthetic compound Ribocil have been shown to target the FMN riboswitch, inhibiting bacterial growth by mimicking the natural ligand and suppressing essential metabolic pathways (Howe et al., 2015; Ott et al., 2009). This mechanism of action provides a pathway for treating infections caused by pathogens that rely on endogenous riboflavin production.
The drug binds to the aptamer domain of the riboswitch, inducing a conformational change in the expression platform that results in premature transcription termination or inhibition of translation initiation, thereby downregulating genes required for riboflavin biosynthesis (Howe et al., 2015).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Flavin mononucleotide riboswitch (FMN riboswitch).